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Abstract
The foundation for adult health is laid in utero and requires a healthy placenta. A common
manifestation of abnormal placental development is impaired fetal growth. While placental pathology
is the final common denominator in many cases of fetal growth restriction, a variety of discreet
lesions have been described involving both the maternal and fetal circulations at their confluence in
the placenta. Detailed examination of the placenta provides a means of elucidating the
pathophysiology of poor fetal growth. This is an essential step in developing effective strategies for
the prediction, prevention, and possible treatment of the growth restricted fetus.
Introduction and context
More than merely a conduit for the provision of oxygen
and nutrients to the fetus, the placenta actively regulates
the passage of substrates necessary for fetal growth and
development. Inparticular, amino acidsare criticalasthey
are precursors for the protein synthesis necessary for
growth. The appropriate balance and quantity of amino
acidsisessentialforfetalandplacentalhealth.Provisionof
amino acids from the maternal circulation into and
through the placenta requires the coordinated activity of
multiple transport proteins, which function differentially
in the microvillus membrane and basal membrane to
provide and maintain the levels of specific amino acids
necessary for normal fetal growth [1]. Intrauterine growth
restriction (IUGR) connotes failure of the fetus to achieve
its growth potential [2]. While genetic abnormalities and
chronic fetal infections may cause IUGR, most cases result
from placental pathology [3]. Both in vitro and in vivo
studies have demonstrated reduced volume and transport
capacity for amino acids in the placentas of IUGR versus
‘appropriate for gestational age’ fetuses [4,5].
The consequences of aberrant fetal growth secondary to
placental dysfunction extend far beyond the intrauterine
phase of our existence. A variety of adult chronic illnesses,
including cardiovascular disease, dyslipidemia, type II
diabetes,and obesity,are now felttobeamanifestation of
fetal malnutrition [6], usually resulting from placental
changes precluding optimum function. The finding that
the placenta is capable of influencing an individual’s
generalhealthyearsfollowingitsrelativelybriefserviceisa
testament to its critical effect on intra- as well as extra-
uterine survival. Growth of the placenta, its blood vessels,
and its blood supply are intertwined such that, under
normal circumstances, fetoplacental growth correlates
with the ability to provide oxygen and nutrients to the
placenta for subsequent transfer to the fetus. As the
intermediarybetweenthemotherandfetus,theplacentais
uniquely qualified to support fetal growth but also
uniquely susceptible to abnormalities affecting the mater-
nal and fetal vascular trees. Despite the intuitive impor-
tance of placental dysmorphology in fetal growth
disorders, a systematic approach to the description of
placental changes has been lacking [7].
Recent advances
An approach to the categorization of placental injury
associated with IUGR has been proposed as follows: (a)
lesions of maternal underperfusion, including decidual
vasculopathy, infarcts, distal villous hypoplasia, increased
syncytial knots, and intervillous fibrin disposition [8]; (b)
fetal vascular obstructive lesions, including large fetal
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obstructive fetal vasculopathy – these changes are the
sequelae of circulatory stasis, vascular injury, and coagu-
lopathies[9];(c)lesionscausingreducedplacentalreserve,
such as extensive perivillous fibrin deposition and
extensive chronic villitis [7]; (d) dysmorphic villous
changes, including villous edema, villous immaturity,
and villous maturation defects characterized by enlarged
dysmorphic villi and capillary vessels surrounded by
edematous stroma [10].
Thefinalcommonpathwayforall ofthese disturbancesof
normal placental anatomy is that they render the placenta
incapable of normal nutrient and gas exchange in the
affected areas. Progression of these changes can result in
chronicundernutritionandfetalgrowthrestriction.Ofthe
placentallesionsassociatedwithIUGR,themostcommon
are those of maternal underperfusion [10,11]. Decidual
vasculopathy refers to a variety of pathologic changes in
the spiral arteries of the decidua that result in diminished
flow through these vessels. Since the spiral arteries supply
oxygen and nutrients to the intervillous space for
subsequent transfer to the fetus, conditions that interfere
with the normal adaptation and perfusion of these vessels
may ultimately impair placental and fetal growth. Normal
placental development is characterized by remodeling of
the spiral arteries. This refers to the process whereby
trophoblastic cells invade and replace the normal mus-
cular intimal lining of the vessel walls, resulting in fixed
dilation that promotes blood flow to the placenta [2].
Acute atherosis, the most common form of decidual
vasculopathy, is characterized by fibrinoid necrosis of the
vessel wall and represents failed conversion of the spiral
arteries. Hypoplasia of the terminal villi is also a feature of
early onset circulatory abnormalities. Such insults are
secondary to abnormal trophoblast infiltration and
implantation. These abnormalities can occur early in
pregnancy, meaning that these placentas are destined to
underachieve, often with demonstrable effects on fetal
growth. The most common maternal conditions asso-
ciated with decidual vasculopathy include hypertensive
disorders (chronic hypertension and pre-eclampsia) and
antiphospholipid syndrome. Other factors implicated in
maldevelopment of the uteroplacental vascular connec-
tion include inherited thrombophilias and type I diabetes
with vascular disease [3,12].
Implications for clinical practice
Fetal growth restriction is associated not only with
perinatal morbidity and mortality, but with a predisposi-
tion to adult chronic illnesses. Normal placental growth
and development is a prerequisite to normal fetal growth
and development. While fetal vascular obstructive lesions
and primary villous pathology, such as perivillous fibrin
deposition and dysmorphic villous changes, may impair
normal fetal growth, most cases of IUGR are secondary to
abnormal placentation resulting from lesions of maternal
underperfusion and compromised uteroplacental circula-
tion. Women at especially high risk for these changes are
those with hypertensive disorders. The pathology of both
chronic hypertension and pre-eclampsia predispose to an
ongoing process of placental vascular changes that
compromise uteroplacental blood flow with detrimental
effects on fetal growth and well being. Diligent examina-
tion of the placenta may provide the only opportunity to
fully understand ‘what went wrong’ in cases of abnormal
fetal growth [13].
Abbreviation
IUGR, intrauterine growth restriction.
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